OVERALL SURVIVAL WITH NIVOLUMAB FOR PATIENTS WITH ADVANCED, PREVIOUSLY TREATED RENAL CELL CARCINOMA

被引：0
|
作者：
Sullivan, W. [1 ]
Lee, D. [1 ]
Willis, A. [1 ]
Doan, J. [2 ]
Gooden, K. [2 ]
Sowdani, A. [3 ]
机构：
[1] BresMed Hlth Solut, Sheffield, S Yorkshire, England
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Bristol Myers Squibb, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN52
引用
收藏
页码：A96 / A96
页数：1
相关论文
共 50 条
  • [1] NICE Guidance - Nivolumab for previously treated advanced renal cell carcinoma: © NICE (2017) Nivolumab for previously treated advanced renal cell carcinoma
    不详
    BJU INTERNATIONAL, 2018, 122 (03) : 362 - 370
  • [2] Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab
    Shao, Ning
    Wan, Fangning
    Zhu, Yao
    Ye, Dingwei
    MEDICAL SCIENCE MONITOR, 2019, 25 : 6518 - 6522
  • [3] Real-world treatment patterns and overall survival in previously treated advanced renal cell carcinoma patients receiving nivolumab in the UK.
    Waddell, Tom
    Fife, Kate
    Griffiths, Richard
    Sharma, Anand
    Dhokia, Poonam
    Gordon, Jason
    Groves, Lara
    Hurst, Michael
    Sugrue, Daniel
    Tsang, Carmen
    Mckenna, Stephen
    Houghton, John
    Carroll, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Nivolumab in previously treated patients with advanced renal cell carcinoma: a guide to its use
    Garnock-Jones K.P.
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2017, 33 (4) : 167 - 173
  • [5] COST EFFECTIVENESS OF NIVOLUMAB FOR PATIENTS WITH ADVANCED, PREVIOUSLY TREATED RENAL CELL CARCINOMA IN SCOTLAND
    Mahon, S.
    Bullement, A.
    Willis, A.
    Sullivan, W.
    Britton, J. A.
    Cox, L.
    Tyas, D.
    Sowdani, A.
    VALUE IN HEALTH, 2017, 20 (09) : A440 - A440
  • [6] Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma
    Chacon, Matias Rodrigo
    Cutuli, Hernan J.
    Bracarda, Sergio
    Maruzzo, Marco
    Bourlon, Maria Teresa
    Jacobs, Carmel
    Perez-Valderrama, Begona
    Magri, Ignacio
    Richardet, Martin
    Centkowski, Piotr
    Fu, Simon Yuen Fai
    Gurman, Pablo
    Konduri, Srivani
    Yu, Zhuoxin
    Vezina, Heather
    George, Saby
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
    McDermott, David F.
    Drake, Charles G.
    Sznol, Mario
    Choueiri, Toni K.
    Powderly, John D.
    Smith, David C.
    Brahmer, Julie R.
    Carvajal, Richard D.
    Hammers, Hans J.
    Puzanov, Igor
    Hodi, F. Stephen
    Kluger, Harriet M.
    Topalian, Suzanne L.
    Pardoll, Drew M.
    Wigginton, Jon M.
    Kollia, Georgia D.
    Gupta, Ashok
    McDonald, Dan
    Sankar, Vindira
    Sosman, Jeffrey A.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) : 2013 - U42
  • [8] Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.
    McDermott, David F.
    Motzer, Roberti.
    Atkins, Michael B.
    Plimack, Elizabeth R.
    Sznol, Mario
    George, Saby
    Drake, Charles G.
    Rini, Brian I.
    Choueiri, Toni K.
    Kuzel, Timothy
    Sosman, Jeffrey Alan
    Smith, David C.
    Vaishampayan, Ulka N.
    Powderly, John D.
    Topalian, Suzanne Louise
    Zhao, Huanyu
    Waxman, Ian M.
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Changes of TCR repertoire in metastatic melanoma and renal cell carcinoma patients treated with nivolumab correlate with overall survival
    Klabusay, M.
    Lemstrova, R.
    Skacel, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S693 - S694
  • [10] Improvements in quality of life and overall survival in patients with advanced renal cell carcinoma treated with nivolumab vs everolimus in the phase Ill CheckMate 025 study
    Gruenwald, V
    Cella, D.
    Nathan, P.
    Doan, J.
    Dastahi, H.
    Taylor, F.
    Bennett, B.
    DeRosa, M.
    Berry, S.
    Broglio, K.
    Berghorn, E.
    Motzer, R. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 265 - 265
12345